L Mineur1, E François2, C Plassot3, J M Phelip4, L Miglianico5, L M Dourthe6, N Bonichon7, L Moreau8, R Guimbaud9, D Smith10, E Achille11, R Hervé12, J M Bons13, S Remy14, R Faroux15, A L Villing16, A Mahamat17, I Rabbia18, P Soulié19, I Baumgaertner20, N Mathé21, L Vazquez1, R Boustany1. 1. Institut Sainte-Catherine, Avignon, France. 2. Lacassagne Anticancer Center, Nice, France. 3. Institut Universitaire de Recherche Clinique, Montpellier, France. 4. Hopital universitaire CHU Nord Saint Etienne, Saint Etienne, France. 5. Saint Gregoire Hospital, Saint Gregoire, France. 6. Strasbourg Oncologie Libérale, Strasbourg, France. 7. Clinique TIVOLI, Bordeaux, France. 8. Clinique les Domes, Clermont-Ferrand, France. 9. CHU Rangueil, Toulouse, France. 10. Hopital Saint-André, Bordeaux, France. 11. Clinique de l'Orangerie, Strasbourg, France. 12. CH Privé Clairval, Marseille, France. 13. Polyclinique Saint-Francois, Desertine, France. 14. Centre d'Oncologie de la côte Basque, Bayonne, France. 15. CHD, La Roche-sur-Yon, France. 16. CH Auxerre, Auxerre, France. 17. CHU Archet II, Nice, France. 18. Cabinet médical, Orange, Paris, France. 19. CLCC Paul Papin, Angers, France. 20. CH Henri Mondor, Créteil, France. 21. Centre Clinique de Soyaux, Soyaux, France.
Abstract
BACKGROUND: Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemotherapy, a standard-of-care first-line treatment regimen for patients with KRAS wt mCRC. PATIENTS AND METHODS: PREMIUM is a prospective, French multicenter, observational study that recruited patients with KRAS wt mCRC scheduled to receive cetuximab, with or without first-line chemotherapy, as part of routine clinical practice, between October 28, 2009 and April 5, 2012 (ClinicalTrials.gov Identifier: NCT01756625). The main endpoints were the factors impacting on efficacy and compliance to cetuximab treatment. Predefined efficacy endpoints were PFS and safety. RESULTS: A total of 493 patients were recruited by 94 physicians. Median follow-up was 12.9 months. Median progression-free survival was 11 months [9.6-12]. In univariate analyses, ECOG performance status (PS), smoking status, primary tumor location, number of metastatic organs, metastasis resectability, surgery, folliculitis, xerosis and paronychia maximum grade, and acne preventive treatment were statistically significant. In multivariate analysis (Hazard Ratios of multivariate stepwise Cox models), ECOG PS, surgery, xerosis and folliculitis were positive prognostics factors for longer PFS. Among all patients, 69 (14%) were non-compliant. In multivariate analysis, no variables were statistically significant. The safety profile of cetuximab was consistent with previous studies. CONCLUSIONS: ECOG PS <2, surgical treatment performed, and maximum grade xerosis or folliculitis developed were predictive factors of cetuximab efficacy on KRAS wt mCRC patients. Unfortunately, we failed in identifying predictive factors for compliance in these patients.
BACKGROUND:Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemotherapy, a standard-of-care first-line treatment regimen for patients with KRAS wt mCRC. PATIENTS AND METHODS: PREMIUM is a prospective, French multicenter, observational study that recruited patients with KRAS wt mCRC scheduled to receive cetuximab, with or without first-line chemotherapy, as part of routine clinical practice, between October 28, 2009 and April 5, 2012 (ClinicalTrials.gov Identifier: NCT01756625). The main endpoints were the factors impacting on efficacy and compliance to cetuximab treatment. Predefined efficacy endpoints were PFS and safety. RESULTS: A total of 493 patients were recruited by 94 physicians. Median follow-up was 12.9 months. Median progression-free survival was 11 months [9.6-12]. In univariate analyses, ECOG performance status (PS), smoking status, primary tumor location, number of metastatic organs, metastasis resectability, surgery, folliculitis, xerosis and paronychia maximum grade, and acne preventive treatment were statistically significant. In multivariate analysis (Hazard Ratios of multivariate stepwise Cox models), ECOG PS, surgery, xerosis and folliculitis were positive prognostics factors for longer PFS. Among all patients, 69 (14%) were non-compliant. In multivariate analysis, no variables were statistically significant. The safety profile of cetuximab was consistent with previous studies. CONCLUSIONS: ECOG PS <2, surgical treatment performed, and maximum grade xerosis or folliculitis developed were predictive factors of cetuximab efficacy on KRAS wt mCRC patients. Unfortunately, we failed in identifying predictive factors for compliance in these patients.
Authors: T Ruers; C Punt; F Van Coevorden; J P E N Pierie; I Borel-Rinkes; J A Ledermann; G Poston; W Bechstein; M A Lentz; M Mauer; E Van Cutsem; M P Lutz; B Nordlinger Journal: Ann Oncol Date: 2012-03-19 Impact factor: 32.976
Authors: Dominik P Modest; Christoph Schulz; Ludwig F von Weikersthal; Detlef Quietzsch; Jobst C von Einem; Andreas Schalhorn; Ursula Vehling-Kaiser; Rüdiger P Laubender; Clemens Giessen; Sebastian Stintzing; Volker Heinemann Journal: Anticancer Drugs Date: 2014-02 Impact factor: 2.248
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: Jeanne Tie; Peter Gibbs; Lara Lipton; Michael Christie; Robert N Jorissen; Antony W Burgess; Matthew Croxford; Ian Jones; Rachel Langland; Suzanne Kosmider; Daniel McKay; Gideon Bollag; Keith Nolop; Oliver M Sieber; Jayesh Desai Journal: Int J Cancer Date: 2011-05-01 Impact factor: 7.396
Authors: E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold Journal: Ann Oncol Date: 2016-07-05 Impact factor: 32.976
Authors: Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: D Arnold; B Lueza; J-Y Douillard; M Peeters; H-J Lenz; A Venook; V Heinemann; E Van Cutsem; J-P Pignon; J Tabernero; A Cervantes; F Ciardiello Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Dalyong Kim; Sun Young Kim; Ji Sung Lee; Yong Sang Hong; Jeong Eun Kim; Kyu-Pyo Kim; Jihun Kim; Se Jin Jang; Young-Kwang Yoon; Tae Won Kim Journal: BMC Gastroenterol Date: 2017-11-23 Impact factor: 3.067